Viral Vector Production Market – Scope of Report
TMR’s report on the global Viral Vector Production Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Viral Vector Production Market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Viral Vector Production Market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Plasmonic Materials market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Plasmonic Materials market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Plasmonic Materials market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Plasmonic Materials market.
The report delves into the competitive landscape of the global Plasmonic Materials market. Key players operating in the global Viral Vector Production Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Viral Vector Production Market profiled in this report.
Key Questions Answered in Global Viral Vector Production Market Report
- What is the sales/revenue generated by Plasmonic Materials across all regions during the forecast period?
- What are the opportunities in the global Plasmonic Materials market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2031?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Viral Vector Production Market – Research Objectives and Research Approach
The comprehensive report on the global Viral Vector Production Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global Viral Vector Production Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Plasmonic Materials market.
Viral Vector Production Market – Scope of Report
TMR’s report on the global Viral Vector Production Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Viral Vector Production Market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Viral Vector Production Market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Plasmonic Materials market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Plasmonic Materials market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Plasmonic Materials market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Plasmonic Materials market.
The report delves into the competitive landscape of the global Plasmonic Materials market. Key players operating in the global Viral Vector Production Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Viral Vector Production Market profiled in this report.
Key Questions Answered in Global Viral Vector Production Market Report
- What is the sales/revenue generated by Plasmonic Materials across all regions during the forecast period?
- What are the opportunities in the global Plasmonic Materials market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2031?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Viral Vector Production Market – Research Objectives and Research Approach
The comprehensive report on the global Viral Vector Production Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global Viral Vector Production Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Plasmonic Materials market.
- 1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global Viral Vector Production Market
- 4. Market Overview
- 4.1. Introduction
- 4.1.1. Vector Type Definition
- 4.1.2. Industry Evolution / Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Viral Vector Production Market Analysis and Forecast, 2017-2031
- 5. Key Insights
- 5.1. Evolution of Gene Therapy
- 5.2. Pipeline Analysis
- 5.3. Regulatory Scenario, by Region/Globally
- 5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
- 6. Global Viral Vector Production Market Analysis and Forecast, by Vector Type
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast, by Vector Type, 2017-2031
- 6.3.1. Adenovirus
- 6.3.2. Adeno-associated virus
- 6.3.3. Retroviruses
- 6.3.4. Others (baculoviruses, lentivirus, etc.)
- 6.4. Market Attractiveness Analysis, by Vector Type
- 7. Global Viral Vector Production Market Analysis and Forecast, by Disease
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast, by Disease, 2017-2031
- 7.3.1. Genetic Diseases
- 7.3.2. Infectious Diseases
- 7.3.3. Cancer
- 7.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
- 7.4. Market Attractiveness Analysis, by Disease
- 8. Global Viral Vector Production Market Analysis and Forecast, by Application
- 8.1. Introduction & Definition
- 8.2. Key Findings / Developments
- 8.3. Market Value Forecast, by Application, 2017-2031
- 8.3.1. Gene Therapy
- 8.3.2. Vaccinology
- 8.4. Market Attractiveness Analysis, by Application
- 9. Global Viral Vector Production Market Analysis and Forecast, by Mode
- 9.1. Introduction & Definition
- 9.2. Key Findings / Developments
- 9.3. Market Value Forecast, by Mode, 2017-2031
- 9.3.1. Transient Transfection
- 9.3.2. Stable Producer Cell Lines
- 9.4. Market Attractiveness Analysis, by Mode
- 10. Global Viral Vector Production Market Analysis and Forecast, by End-user
- 10.1. Introduction & Definition
- 10.2. Key Findings / Developments
- 10.3. Market Value Forecast, by End-user, 2017-2031
- 10.3.1. Pharmaceutical & Biotechnology Companies
- 10.3.2. Academic & Research Institutes
- 10.3.3. CROs & CDMOs
- 10.4. Market Attractiveness Analysis, by End-user
- 11. Global Viral Vector Production Market Analysis and Forecast, by Region
- 11.1. Key Findings
- 11.2. Market Value Forecast, by Region
- 11.2.1. North America
- 11.2.2. Europe
- 11.2.3. Asia Pacific
- 11.2.4. Latin America
- 11.2.5. Middle East & Africa
- 11.3. Market Attractiveness Analysis, by Region
- 12. North America Viral Vector Production Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Key Findings
- 12.2. Market Value Forecast, by Vector Type, 2017-2031
- 12.2.1. Adenovirus
- 12.2.2. Adeno-associated virus
- 12.2.3. Retroviruses
- 12.2.4. Others (baculoviruses, lentivirus, etc.)
- 12.3. Market Value Forecast, by Disease, 2017-2031
- 12.3.1. Genetic Diseases
- 12.3.2. Infectious Diseases
- 12.3.3. Cancer
- 12.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
- 12.4. Market Value Forecast, by Application, 2017-2031
- 12.4.1. Gene Therapy
- 12.4.2. Vaccinology
- 12.5. Market Value Forecast, by Mode, 2017-2031
- 12.5.1. Transient Transfection
- 12.5.2. Stable Producer Cell Lines
- 12.6. Market Value Forecast, by End-user, 2017-2031
- 12.6.1. Pharmaceutical & Biotechnology Companies
- 12.6.2. Academic & Research Institutes
- 12.6.3. CROs & CDMOs
- 12.7. Market Value Forecast, by Country, 2017-2031
- 12.7.1. U.S.
- 12.7.2. Canada
- 12.8. Market Attractiveness Analysis
- 12.8.1. By Vector Type
- 12.8.2. By Disease
- 12.8.3. By Application
- 12.8.4. By Mode
- 12.8.5. By End-user
- 12.8.6. By Country
- 13. Europe Viral Vector Production Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Key Findings
- 13.2. Market Value Forecast, by Vector Type, 2017-2031
- 13.2.1. Adenovirus
- 13.2.2. Adeno-associated virus
- 13.2.3. Retroviruses
- 13.2.4. Others (baculoviruses, lentivirus, etc.)
- 13.3. Market Value Forecast, by Disease, 2017-2031
- 13.3.1. Genetic Diseases
- 13.3.2. Infectious Diseases
- 13.3.3. Cancer
- 13.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
- 13.4. Market Value Forecast, by Application, 2017-2031
- 13.4.1. Gene Therapy
- 13.4.2. Vaccinology
- 13.5. Market Value Forecast, by Mode, 2017-2031
- 13.5.1. Transient Transfection
- 13.5.2. Stable Producer Cell Lines
- 13.6. Market Value Forecast, by End-user, 2017-2031
- 13.6.1. Pharmaceutical & Biotechnology Companies
- 13.6.2. Academic & Research Institutes
- 13.6.3. CROs & CDMOs
- 13.7. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.7.1. Germany
- 13.7.2. U.K.
- 13.7.3. France
- 13.7.4. Spain
- 13.7.5. Italy
- 13.7.6. Rest of Europe
- 13.8. Market Attractiveness Analysis
- 13.8.1. By Vector Type
- 13.8.2. By Disease
- 13.8.3. By Application
- 13.8.4. By Mode
- 13.8.5. By End-user
- 13.8.6. By Country/Sub-region
- 14. Asia Pacific Viral Vector Production Market Analysis and Forecast
- 14.1. Introduction
- 14.1.1. Key Findings
- 14.2. Market Value Forecast, by Vector Type, 2017-2031
- 14.2.1. Adenovirus
- 14.2.2. Adeno-associated virus
- 14.2.3. Retroviruses
- 14.2.4. Others (baculoviruses, lentivirus, etc.)
- 14.3. Market Value Forecast, by Diseases, 2017-2031
- 14.3.1. Genetic Diseases
- 14.3.2. Infectious Diseases
- 14.3.3. Cancer
- 14.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
- 14.4. Market Value Forecast, by Application, 2017-2031
- 14.4.1. Gene Therapy
- 14.4.2. Vaccinology
- 14.5. Market Value Forecast, by Mode, 2017-2031
- 14.5.1. Transient Transfection
- 14.5.2. Stable Producer Cell Lines
- 14.6. Market Value Forecast, by End-user, 2017-2031
- 14.6.1. Pharmaceutical & Biotechnology Companies
- 14.6.2. Academic & Research Institutes
- 14.6.3. CROs & CDMOs
- 14.7. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.7.1. China
- 14.7.2. Japan
- 14.7.3. India
- 14.7.4. Australia & New Zealand
- 14.7.5. Rest of Asia Pacific
- 14.8. Market Attractiveness Analysis
- 14.8.1. By Vector Type
- 14.8.2. By Disease
- 14.8.3. By Application
- 14.8.4. By Mode
- 14.8.5. By End-user
- 14.8.6. By Country/Sub-region
- 15. Latin America Viral Vector Production Market Analysis and Forecast
- 15.1. Introduction
- 15.1.1. Key Findings
- 15.2. Market Value Forecast, by Vector Type, 2017-2031
- 15.2.1. Adenovirus
- 15.2.2. Adeno-associated virus
- 15.2.3. Retroviruses
- 15.2.4. Others (baculoviruses, lentivirus, etc.)
- 15.3. Market Value Forecast, by Disease, 2017-2031
- 15.3.1. Genetic Diseases
- 15.3.2. Infectious Diseases
- 15.3.3. Cancer
- 15.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
- 15.4. Market Value Forecast, by Application, 2017-2031
- 15.4.1. Gene Therapy
- 15.4.2. Vaccinology
- 15.5. Market Value Forecast, by Mode, 2017-2031
- 15.5.1. Transient Transfection
- 15.5.2. Stable Producer Cell Lines
- 15.6. Market Value Forecast, by End-user, 2017-2031
- 15.6.1. Pharmaceutical & Biotechnology Companies
- 15.6.2. Academic & Research Institutes
- 15.6.3. CROs & CDMOs
- 15.7. Market Value Forecast, by Country/Sub-region, 2017-2031
- 15.7.1. Brazil
- 15.7.2. Mexico
- 15.7.3. Rest of Latin America
- 15.8. Market Attractiveness Analysis
- 15.8.1. By Vector Type
- 15.8.2. By Disease
- 15.8.3. By Application
- 15.8.4. By Mode
- 15.8.5. By End-user
- 15.8.6. By Country/Sub-region
- 16. Middle East & Africa Viral Vector Production Market Analysis and Forecast
- 16.1. Introduction
- 16.1.1. Key Findings
- 16.2. Market Value Forecast, by Vector Type, 2017-2031
- 16.2.1. Adenovirus
- 16.2.2. Adeno-associated virus
- 16.2.3. Retroviruses
- 16.2.4. Others (baculoviruses, lentivirus, etc.)
- 16.3. Market Value Forecast, by Disease, 2017-2031
- 16.3.1. Genetic Diseases
- 16.3.2. Infectious Diseases
- 16.3.3. Cancer
- 16.3.4. Others (metabolic diseases, neurodegenerative disorders, etc.)
- 16.4. Market Value Forecast, by Application, 2017-2031
- 16.4.1. Gene Therapy
- 16.4.2. Vaccinology
- 16.5. Market Value Forecast, by Mode, 2017-2031
- 16.5.1. Transient Transfection
- 16.5.2. Stable Producer Cell Lines
- 16.6. Market Value Forecast, by End-user, 2017-2031
- 16.6.1. Pharmaceutical & Biotechnology Companies
- 16.6.2. Academic & Research Institutes
- 16.6.3. CROs & CDMOs
- 16.7. Market Value Forecast, by Country/Sub-region, 2017-2031
- 16.7.1. GCC Countries
- 16.7.2. South Africa
- 16.7.3. Rest of Middle East & Africa
- 16.8. Market Attractiveness Analysis
- 16.8.1. By Vector Type
- 16.8.2. By Disease
- 16.8.3. By Application
- 16.8.4. By Mode
- 16.8.5. By End-user
- 16.8.6. By Country/Sub-region
- 17. Competition Landscape
- 17.1. Market Player - Competition Matrix (By Tier and Size of companies)
- 17.2. Market Share Analysis By Company (2021)
- 17.3. Company Profiles
- 17.3.1. Pfizer, Inc.
- 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.1.2. Test Type Portfolio
- 17.3.1.3. Financial Overview
- 17.3.1.4. SWOT Analysis
- 17.3.1.5. Strategic Overview
- 17.3.2. Johnson & Johnson
- 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.2.2. Test Type Portfolio
- 17.3.2.3. Financial Overview
- 17.3.2.4. SWOT Analysis
- 17.3.2.5. Strategic Overview
- 17.3.3. AstraZeneca
- 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.3.2. Test Type Portfolio
- 17.3.3.3. Financial Overview
- 17.3.3.4. SWOT Analysis
- 17.3.3.5. Strategic Overview
- 17.3.4. Sanofi
- 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.4.2. Test Type Portfolio
- 17.3.4.3. Financial Overview
- 17.3.4.4. SWOT Analysis
- 17.3.4.5. Strategic Overview
- 17.3.5. Novartis AG
- 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.5.2. Test Type Portfolio
- 17.3.5.3. Financial Overview
- 17.3.5.4. SWOT Analysis
- 17.3.5.5. Strategic Overview
- 17.3.6. Spark Therapeutics, Inc. (F. Hoffmann-La Roche Ltd.)
- 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.6.2. Test Type Portfolio
- 17.3.6.3. Financial Overview
- 17.3.6.4. SWOT Analysis
- 17.3.6.5. Strategic Overview
- 17.3.7. GlaxoSmithKline plc
- 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.7.2. Test Type Portfolio
- 17.3.7.3. Financial Overview
- 17.3.7.4. SWOT Analysis
- 17.3.7.5. Strategic Overview
- 17.3.8. Merck KGaA (Merck & Co., Inc.)
- 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.8.2. Test Type Portfolio
- 17.3.8.3. Financial Overview
- 17.3.8.4. SWOT Analysis
- 17.3.8.5. Strategic Overview
- 17.3.9. Lonza
- 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.9.2. Test Type Portfolio
- 17.3.9.3. Financial Overview
- 17.3.9.4. SWOT Analysis
- 17.3.9.5. Strategic Overview
- 17.3.10. FUJIFILM Diosynth Biotechnologies Inc.
- 17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.10.2. Test Type Portfolio
- 17.3.10.3. Financial Overview
- 17.3.10.4. SWOT Analysis
- 17.3.10.5. Strategic Overview
- 17.3.11. Oxford Biomedica plc
- 17.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.11.2. Test Type Portfolio
- 17.3.11.3. Financial Overview
- 17.3.11.4. SWOT Analysis
- 17.3.11.5. Strategic Overview
- 17.3.12. Amgen Inc.
- 17.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.12.2. Test Type Portfolio
- 17.3.12.3. Financial Overview
- 17.3.12.4. SWOT Analysis
- 17.3.12.5. Strategic Overview
- 17.3.13. Ferring B.V.
- 17.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.13.2. Test Type Portfolio
- 17.3.13.3. Financial Overview
- 17.3.13.4. SWOT Analysis
- 17.3.13.5. Strategic Overview
- 17.3.14. uniQure N.V.
- 17.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.14.2. Test Type Portfolio
- 17.3.14.3. Financial Overview
- 17.3.14.4. SWOT Analysis
- 17.3.14.5. Strategic Overview
- 17.3.15. bluebird bio, Inc.
- 17.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.15.2. Test Type Portfolio
- 17.3.15.3. Financial Overview
- 17.3.15.4. SWOT Analysis
- 17.3.15.5. Strategic Overview
- 17.3.16. GenScript ProBio
- 17.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.16.2. Test Type Portfolio
- 17.3.16.3. Financial Overview
- 17.3.16.4. SWOT Analysis
- 17.3.16.5. Strategic Overview
- 17.3.17. Thermo Fisher Scientific, Inc.
- 17.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.17.2. Test Type Portfolio
- 17.3.17.3. Financial Overview
- 17.3.17.4. SWOT Analysis
- 17.3.17.5. Strategic Overview
- 17.3.18. Gamaleya Research Institute
- 17.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.18.2. Test Type Portfolio
- 17.3.18.3. Financial Overview
- 17.3.18.4. SWOT Analysis
- 17.3.18.5. Strategic Overview
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook